Candriam S.C.A. Cuts Position in Kura Oncology, Inc. (NASDAQ:KURA)

Candriam S.C.A. lessened its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 53.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 422,652 shares of the company’s stock after selling 483,830 shares during the period. Candriam S.C.A. owned approximately 0.54% of Kura Oncology worth $3,681,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of KURA. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Kura Oncology by 35.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after purchasing an additional 7,722 shares during the period. Intech Investment Management LLC bought a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $298,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Kura Oncology by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after purchasing an additional 14,106 shares during the period. Algert Global LLC raised its holdings in shares of Kura Oncology by 4.4% in the 3rd quarter. Algert Global LLC now owns 272,276 shares of the company’s stock worth $5,320,000 after purchasing an additional 11,493 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $596,000.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 in the last three months. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

KURA has been the topic of a number of research reports. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Stock Down 2.2 %

KURA opened at $7.53 on Friday. The company has a fifty day moving average price of $8.00 and a 200-day moving average price of $13.38. The firm has a market capitalization of $585.56 million, a P/E ratio of -3.19 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a one year low of $6.98 and a one year high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. Equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.